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Abstract 
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Kingdom continue to rise, particularly in young men, and alcohol is often taken with the overdose.2 In 
general the severity of poisoning has diminished over the past 10 years with the introduction of safer 
drugs, such as newer serotonin reuptake inhibitors, but the total number of deaths from poisoning in the 
United Kingdom remains steady at 4000 per year, and the commonest cause of death by poisoning is 
carbon monoxide.2 3 This article highlights several specific advances in the management of poisoning 
over the past two or three years. 
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Clinical review
Recent advances
Management of self poisoning
Alison L Jones, Glyn Volans
Introduction
Around 15%-20% of the workload of medical units
and 10% of the workload of accident and emergency
departments in the United Kingdom are due to self
poisoning.1 2 Episodes of self poisoning in the United
Kingdom continue to rise, particularly in young men,
and alcohol is often taken with the overdose.2 In
general the severity of poisoning has diminished over
the past 10 years with the introduction of safer drugs,
such as newer serotonin reuptake inhibitors, but the
total number of deaths from poisoning in the United
Kingdom remains steady at 4000 per year, and the
commonest cause of death by poisoning is carbon
monoxide.2 3 This article highlights several specific
advances in the management of poisoning over the
past two or three years.
Methods
We searched Medline and Embase with the keywords
“poisoning,” “intoxication,” “toxin,” and “overdose.” We
included topics as a result of discussion with colleagues
in clinical toxicology in the United Kingdom, Europe,
Australia, and the United States.
New guidelines on gut decontamination
The American Academy of Clinical Toxicology and the
European Association of Poisons Centres and Clinical
Toxicologists have recently produced new guidelines
on gut decontamination on the basis of consensus and
evidence based statements.4–6 It is important to under-
stand the advances in understanding and changes in
practice that come from the guidelines, but the
evidence base for them is limited.4–7
Activated charcoal
Activated charcoal should be given as a single dose
(50 g for an adult, 1 g/kg body weight for a child up to
12 years) up to 1 hour after ingestion of a substantial
amount of toxin.4 Beyond this time adsorption is
reduced.4 8 What constitutes a substantial amount of
toxin depends on the toxin but in general it is a dose
expected to cause moderate to severe toxicity. The
guidelines do not apply to agents for which multiple
dose charcoal would be beneficial or for substances
that are not readily adsorbed to charcoal (box 1).4 5
Charcoal should never be given if the airway cannot be
protected, as aspiration pneumonitis is a risk.9
Multiple doses of activated charcoal (adults: 50 g
immediately followed by 25 g every 2 hours or 50 g
every 4 hours; children: 1 g/kg body weight followed
by 1 g/kg body weight every 4 hours) should be
considered for the adsorption and enhanced elimina-
tion of certain toxins (box 2).5 The role of more than
one dose of activated charcoal in salicylate poisoning
remains controversial, but the current guideline states
that single dose charcoal should be used up to 1 hour
after ingestion.4 5
Gastric lavage
Gastric lavage is only used up to 1 hour after ingestion
of a substantial amount of toxin; many clinical
toxicologists rarely use this method now.6 One study
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showed that gastric emptying by lavage and emesis
failed to remove all the tablets taken by patients, and
that a large residue often remained.10 An Australian
study showed that outcome in poisoning was not
improved by gastric lavage and activated charcoal ver-
sus activated charcoal alone; however, the number of
patients that were seriously poisoned was compara-
tively small.11 Gastric lavage is absolutely contraindi-
cated after ingestion of corrosive substances and
comparatively contraindicated after ingestion of
hydrocarbon solvents, such as white spirit, because of
the risk of lipoid pneumonitis.6
Emetics
Syrup of ipecacuanha is now rarely used as an emetic
as there is no evidence that it decreases morbidity or
mortality in poisoning. Additionally, emetics may
increase morbidity by causing symptom free patients
to become nauseated and to vomit.12 It is also difficult
to give activated charcoal after an emetic.12
Whole bowel irrigation
In whole bowel irrigation a solution of polyethylene
glycol is given orally or by nasogastric tube (2 litres per
hour in adults) until the rectal effluent becomes clear
(usually after 2-6 hours). It is contraindicated in
patients with bowel obstruction, perforation, ileus,
haemodynamic instability, or where the airway cannot
be protected.13 Polyethylene glycol should be consid-
ered when patients have ingested potentially serious
substances—for example, sustained release or enteric
coated preparations. It is also of theoretical value after
such ingestions of lithium, iron, arsenic, lead oxide, and
zinc sulphate.13 Polyetheylene glycol or laxatives are
sometimes used in body packers to remove packets
that are beyond the pylorus, although one report
described the death of a body packer when ingested
condoms dissolved after paraffin was given.14 Packets in
the stomach are best removed endoscopically, and
packets in the small or large intestine that contain
potentially lethal amounts of drugs should be removed
surgically.15 16 The alternative is to wait for the packet to
pass through the body naturally, which it is possible to
do with less toxic drugs such as cannabis.
Carbon monoxide poisoning
Hyperbaric oxygen
Carbon monoxide causes severe hypoxia by forming
carboxyhaemoglobin, which impairs oxygen delivery
from blood to tissues and prevents the use of available
oxygen by combining with cytochrome oxidase.17
Death may result from cardiac and neurological seque-
lae acutely but subacute and chronic exposure are also
important. The scientific rationale for hyperbaric
oxygen improving outcome in carbon monoxide
poisoning is that the half life of carboxyhaemoglobin is
reduced, and that the reduced amounts of carbon
monoxide bind to the enzyme.17 18 To date, however,
five randomised trials have disagreed on whether treat-
ment with hyperbaric oxygen works in clinical
practice.19–23 Limitations to the trials were too few
patients, inclusion of patients exposed to other toxins
in fires, and different protocols for hyperbaric oxygen
therapy. The latest study suggested that hyperbaric
oxygen therapy might be harmful, but only 46% of
patients attended follow up.23 The current recommen-
dation is that hyperbaric oxygen therapy should be
considered if a patient has been unconscious at any
stage since exposure, if carboxyhaemoglobin concen-
trations have exceeded 40% at any time, or if there are
neurological or psychiatric features. The logistical diffi-
culties in transporting patients to hyperbaric oxygen
chambers should not be underestimated.
Paracetamol poisoning
Paracetamol continues to generate the greatest
number of emergency inquiries to the National
Poisons Information Service of any single agent, and it
constitutes 48% of hospital admissions for poisoning
in the United Kingdom.24 A practical wall chart for
management of paracetamol poisoning has been
approved by physicians of the National Poisons Infor-
mation Service, paediatricians, and accident and emer-
gency clinicians.25
Patients at increased risk from paracetamol
poisoning are those with enzyme induction such as
patients taking anticonvulsants or those with glutathi-
one depletion such as anorexic patients. Such patients
should receive N-acetylcysteine at lower plasma
paracetamol concentrations than patients at normal
risk.25–27 Defining those at risk is not new, but there is
greater awareness both of who they are and of failure
to provide appropriate antidotal treatment. The main
message in paracetamol poisoning is “if in doubt, treat
with N-acetylcysteine.” Anaphylactoid reactions occur
in about 5% of patients given N-acetylcysteine, often
within an hour of starting the infusion.28
Management difficulties in paracetamol poisoning
include patients presenting 15 hours or more after
ingestion of the drug or patients taking staggered
overdoses—in excess of 150 mg/kg/day body weight or
12 g for an adult, whichever is the lesser. A poisons
centre or a liver transplant unit should be contacted if
there is evidence of hepatotoxicity or doubt about its
management. This ensures that referral takes place
Box 1: Substances not readily adsorbed to
charcoal
Ferrous salts
Lithium preparations
Potassium salts
Ethanol
Methanol
Ethylene glycol
Acids
Alkalis
Fluorides
Organic solvents
Mercury and its salts
Lead and its salts
Box 2: Indications for multiple dose activated
charcoal
Slow release preparations such as theophylline
(but not lithium)
Carbamazepine
Dapsone
Digoxin
Paraquat
Phenobarbitone
Quinine
The fungus Amanita phalloides
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before the criteria for liver transplantation are met (a
prothrombin time greater than 100 seconds, serum
creatinine concentration greater than 300 ìmol/l, and
grade III or IV encephalopathy or a pH of less than 7.3
at 24 hours or more after ingestion, after correction of
hypovolaemia) and that intensive care support is
appropriate.29 N-acetylcysteine is also used in patients
with fulminant hepatic failure (encephalopathy and
renal failure) due to paracetamol and it is not acting by
glutathione repletion at this stage. N-acetylcysteine
may scavenge free radicals or exert some haemody-
namic effect, although its role is debatable.30–32
Drugs of misuse
Ecstasy
Drugs of misuse continue to present problems,
particularly in inner city areas. Ecstasy (methylenedi-
oxymethamphetamine or MDMA) causes dehydration
with hyperthermia, agitation, and fits. Deaths still result
from ecstasy poisoning. Treatments that may decrease
mortality, particularly if the rectal temperature exceeds
40oC, include active cooling measures such as cool
intravenous fluids, and use of the muscle relaxant dan-
trolene.33 The extent to which dantrolene is of value is,
however, in doubt and it has dose dependent adverse
effects such as hepatitis.33 Hepatotoxicity has occurred
with ecstasy poisoning, and this has been treated with
liver transplantation.34 35 Other features of ecstasy
poisoning include hyponatraemia, cerebral infarction
or haemorrhage due to uncontrolled hypertension, or
vasculitis.35 Many substances are now added to ecstasy
tablets such as caffeine and ketamine.36 Ketamine is a
veterinary anaesthetic, which in man causes a dissocia-
tive state and has led to it being used for “date rapes.”36
Ketamine has also resulted in accidents as the drug
causes pain free floating sensations with vivid dreams.
A current vogue is the use of sidafenil (Viagra) with
ecstasy for enhanced effects, so called sextasy.
Liquid Ecstasy
Another recent drug of misuse is gammahydroxybutyric
acid (GHB or “liquid ecstasy”).37 The drug is dissolved in
water to produce a clear liquid and is consumed until a
“high” is reached.37 Liquid ecstasy increases intracerebral
dopamine and if taken in excess causes drowsiness
followed by seizures, hypoventilation, and loss of
consciousness.37 38 The response is unpredictable, and
coma and seizures have been produced by as little as 5
ml in an adult. Liquid ecstasy acts synergistically with
ethanol to produce central nervous system and respira-
tory depression.37 38 Naloxone has been shown to reverse
some of the effects of liquid ecstasy in animals, but its
efficacy in man is unknown.38
Ethylene glycol and methanol poisoning
Poisoning with ethylene glycol and methanol have tra-
ditionally been treated by a combination of haemodi-
alysis to remove toxic metabolites and ethanol to
competitively inhibit enzymes responsible for produc-
tion of the toxic metabolites. Like ethanol,
4-methylpyrazole is a competitive inhibitor of alcohol
dehydrogenase, blocking the metabolism of ethylene
glycol into its toxic metabolites glycolate and oxalate.39
4-Methylpyrazole is licensed for use in several
countries, including the United States and United
Kingdom, and is used to treat severe methanol or eth-
ylene glycol poisoning. Compared with treatment with
ethanol it has the advantage of reduced central
nervous system depression, although haemodialysis
may still be needed to remove accumulated metabo-
lites and for the management of renal failure.39 40
Poisons databases
In the United Kingdom several databases have been
developed to meet the increasing needs of doctors and
nurses for information on poisons (box 3). In addition,
easy internet access to a wide variety of sources of poi-
sons information, including lethal “recipes,” enables
people both to be better informed and to be at greater
risk from serious poisoning.
Self poisoning is an important clinical problem,
and several advances in recent years have been
initiated by cases reports, which are then developed
into multicentre—often multinational—collaborations.
Information on the management of particularly
unusual or serious cases can be obtained from the
National Poisons Information Service.
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Lesson of the week
Insulin as a substance of misuse in a patient with insulin
dependent diabetes mellitus
Eugene M Cassidy, D J O’Halloran, Siobhán Barry
The relation between substance misuse and poor com-
pliance with treatment is well established in both gen-
eral medicine and psychiatry.1 2 Although young
patients with insulin dependent diabetes mellitus may
have lower rates of comorbid substance misuse,3 there
is direct evidence that their compliance with treatment
is poor.4 Patients with insulin dependent diabetes mel-
litus have an increased risk of developing a psychiatric
disorder, particularly in the early course of their
illness,3 and treating the psychiatric disorder improves
glycaemic control.5
Hypoglycaemic events are common in people with
insulin dependent diabetes mellitus6 and may be associ-
ated with cognitive, affective, and sometimes life
threatening sequelae.7 Specific mood changes caused by
changes in blood glucose concentrations are idiosyn-
cratic, and although negative affective states are the most
common, positive changes such as giddiness and
euphoria are also seen.8 Although there is a strong rela-
tion between severe hypoglycaemia and tight glycaemic
control,9 cases of deliberate misuse of insulin have been
reported. Typically, these patients either attempt suicide
or feign illness.10 We report the rare case of a patient with
insulin dependent diabetes mellitus and no history of a
psychiatric disorder who misused insulin regularly over
a two year period for its euphoric effects. The
consequences were ultimately serious.
Case report
A 30 year old man with insulin dependent diabetes
mellitus was admitted to hospital. He had lost
consciousness for two hours as a result of severe
hypoglycaemia, and had then experienced prolonged
confusion. The man, a college lecturer, was unmarried.
Since his diagnosis three years previously, his diabetic
control had been erratic (HbAlc values ranged from 8%
Clinical review
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with poor
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